Wernsdorfer Walther H
Department of Specific Prophylaxis and Tropical Medicine, University of Vienna, Kinderspitalgasse 15, A-1095 Vienna, Austria.
Expert Rev Anti Infect Ther. 2004 Apr;2(2):181-96. doi: 10.1586/14787210.2.2.181.
Coartemether (Riamet, Coartem, Novartis), a tablet formulation of artemether and lumefantrine, is a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated falciparum malaria that is resistant to other antimalarials. Initial clinical-parasitological response relies mainly on the artemether component, while lumefantrine effects radical cure. The absorption of lumefantrine is poor during the fasting state, the normal condition in acutely ill malaria patients, but with return to normal diet it becomes adequate. This highlights the need for an appropriate adjustment of the dose regimen. In the area where Plasmodium falciparum shows the highest degree of multidrug resistance worldwide, the best results (99% cure) were obtained with a six-dose regimen given over 5 days. Extensive cardiological investigations have demonstrated the high cardiac safety of coartemether.
蒿甲醚-本芴醇(Riamet、Coartem,诺华公司)是一种由蒿甲醚和本芴醇制成的片剂,是一种耐受性良好、起效迅速且有效的血液裂殖体杀灭药物,主要用于治疗对其他抗疟药耐药的非复杂性恶性疟。最初的临床寄生虫学反应主要依赖蒿甲醚成分,而本芴醇则起根治作用。本芴醇在禁食状态下吸收较差,而急性疟疾患者通常处于这种状态,但恢复正常饮食后吸收就会变得充足。这突出了调整给药方案的必要性。在全球恶性疟原虫多重耐药程度最高的地区,采用5天内服用6剂的方案可取得最佳效果(治愈率99%)。广泛的心脏学研究表明蒿甲醚-本芴醇具有很高的心脏安全性。